Compare BBCP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | REPL |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 407.1M |
| IPO Year | 2017 | 2018 |
| Metric | BBCP | REPL |
|---|---|---|
| Price | $10.38 | $9.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $8.25 | $5.67 |
| AVG Volume (30 Days) | 119.6K | ★ 8.0M |
| Earning Date | 06-04-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $1.50 |
| 52 Week High | $8.13 | $13.24 |
| Indicator | BBCP | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 86.69 | 74.81 |
| Support Level | $6.71 | $9.50 |
| Resistance Level | N/A | $10.67 |
| Average True Range (ATR) | 0.46 | 0.74 |
| MACD | 0.19 | 0.54 |
| Stochastic Oscillator | 66.26 | 79.97 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.